Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 6Glioblastoma 5Childhood Brain Neoplasm 2Neurodegenerative Diseases 1Ischemic Stroke 1Hypoxia 1Hemorrhagic Stroke 1Glioma 1Cranial Nerve Diseases 1Central Nervous System Vascular Malformations 1Central Nervous System Neoplasms 1Central Nervous System Infections 1Brain Injuries 1Adult Brain Glioblastoma 1

Interventions

Radiotherapy 122Temozolomide 110Carboplatin 53Filgrastim 46Vincristine 43Etoposide 39Cyclophosphamide 37Chemotherapy, Adjuvant 37Cisplatin 36Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 24Lomustine 22Thiotepa 21Methotrexate 20Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Drug Therapy 13Topotecan 12Paclitaxel 12Ifosfamide 12Thalidomide 11Radiation 11sargramostim 10Specimen Handling 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Ferrosoferric Oxide × CNS × Clear all
NCT03270059 2026-02-27

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

OHSU Knight Cancer Institute

Phase 2 Recruiting
150 enrolled
CNS

Brain Neoplasms, Cranial Nerve Diseases, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡